Hair Loss Statistics in Liverpool

The waiting room at Exchange Flags tells you something the national statistics don’t. Most of the men sitting there are younger than you’d expect: late twenties, early thirties, a few still at university. A handful in their forties. Rarely anyone older than that, not because older men stop caring, but because most of them made peace with it years ago or had already done something about it elsewhere.

Liverpool has a younger population than most UK cities. The 2021 Census put the city’s median age at 35, against a national England figure of 40. That gap sounds modest but it matters considerably when you’re looking at hair loss, because the years between 25 and 40 are when androgenetic alopecia is most actively progressing in the men who are going to be significantly affected by it. A younger city means a larger share of its male population is right in that window.

The condition nobody expects to get young

Androgenetic alopecia (the hereditary sensitivity to dihydrotestosterone, or DHT, that causes the follicles to miniaturise) doesn’t wait until middle age. The American Hair Loss Association puts two thirds of men at some degree of noticeable thinning by 35. By 50, that figure sits somewhere between 50 and 85% depending on the population studied and the measurement criteria used. Plenty of the men we see in Liverpool had their first signs in their mid-twenties and spent the better part of a decade either not noticing or deciding not to act.

The genetics involved are more complicated than most people think. The maternal grandfather connection gets repeated as though it’s a reliable rule. It’s not, really. Hair loss inheritance draws on multiple gene variants from both parents, and the outcomes between brothers with identical family histories can differ substantially. Severity, timing, the specific pattern of loss: none of it follows a clean line.

The other kind, and why people miss it

Telogen effluvium gets far less attention than pattern baldness but it’s the second most common presentation we assess. It’s not hereditary. It’s a stress response: the body shunting a disproportionate number of follicles into the resting phase simultaneously in response to a physical or psychological shock. Surgery. A serious illness. Rapid weight loss. A thyroid disorder flaring. Months of sustained psychological stress.

The thing that makes it genuinely confusing to deal with is the delay. Shedding typically begins eight to twelve weeks after the triggering event, sometimes longer. So the person sitting in front of us is usually looking for what changed last month, and the actual cause was something that happened the season before. That timing gap is why telogen effluvium so often gets misidentified, or just attributed to stress in a vague, unhelpful way without anyone identifying the specific trigger.

Women, and why this is routinely undercounted

The NHS figure for female hair loss in the UK is around 8 million women affected. That number is almost certainly an undercount. Female pattern hair loss tends to present as diffuse thinning across the crown and top of the scalp rather than the defined recession seen in men , the Ludwig pattern rather than Hamilton-Norwood. It’s easier to disguise. Styling compensates for it. The parting widens gradually enough that many women normalise it over years before deciding to see someone.

Hormonal factors are central to the female picture in a way they aren’t for men. Menopause is the most significant driver: the reduction in oestrogen shifts the hormonal balance toward androgens, which increases DHT activity in susceptible follicles. Post-pregnancy shedding is common, usually temporary, but occasionally the trigger for longer-term changes. Polycystic ovary syndrome raises androgen levels and is worth ruling out in younger women presenting with diffuse thinning. Alopecia areata (autoimmune, patchy, follows a different clinical path entirely) affects women too and gets grouped in with other causes in a way that probably inflates the already uncertain figures.

We see women regularly at the Liverpool clinic. It’s not a niche part of the practice.

On the medication question

The two drugs that come up in almost every consultation are finasteride and minoxidil. Finasteride works upstream: it inhibits the enzyme that converts testosterone to DHT, reducing the signal that’s miniaturising the follicles. Minoxidil acts at the follicle level, extending the active growth phase. Used together, they tend to produce better outcomes than either alone.

What they don’t do is restore hair in areas that have already been lost. That’s the single most important thing to understand about both medications: they’re for slowing what’s still happening, not recovering what’s gone. A significant number of patients use one or both alongside surgery, which is usually the right approach when loss is still progressing.

Surgery: what the realistic picture looks like

FUE is the method we use most. Follicular units extracted individually from the donor zone (the back and sides, where the hair is genetically resistant to DHT) and placed into the thinning areas. Graft survival in properly performed FUE sits between 90 and 95% in the clinical literature, meaning the transplanted hair is overwhelmingly likely to establish and continue growing. The ISHRS reported over 650,000 hair transplant procedures performed globally in a single year in its 2023 Practice Census, a figure that’s been rising consistently for over a decade.

FUT (the strip method) produces a linear scar but remains the better option for some patients who need a high graft count in a single session. The choice between the two comes down to specifics, not a blanket preference.

Frontal work and crown work need different planning conversations. A hairline restoration targets the front edge and tends to be high impact relative to the graft count involved: it’s what people see immediately, in every mirror and photograph. Crown restoration covers more surface area and carries a longer planning horizon, because crown loss often continues after a procedure if the underlying progression hasn’t been addressed. Pricing varies with graft count and technique: there’s no single figure that applies universally.

A free consultation is where the planning actually starts. A surgeon looks at what’s there, grades the loss, assesses the donor, and gives you a straight account of what’s realistic. No commitment follows from that conversation unless you want it to.

References